This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognizing you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Experts
Sarah Ball
Vice President & Lead Scientific/Epidemiology Advisor
Contact
SarahBall@xyschool.netOverview
Sarah Ball, ScD, MS, MPH, is a Vice President for Clinical Research and Lead Scientific/Epidemiology Advisor for 趣赢平台’s Health Sector. She is an epidemiologist who is passionate about the innovative design and implementation of clinical research, developing creative solutions for complex data collection, and ensuring the synthesis and timely dissemination of research findings. With a background in maternal and child health and epidemiology, combined with more than a decade of experience in influenza and other respiratory diseases, her experience spans epidemiologic research, clinical study implementation, and program evaluation.
As Lead Scientific/Epidemiology Advisor, Ball is responsible for envisioning and expanding research capabilities (human, methodological, and technological) across 趣赢平台’s Health Sector, developing evidence of the validity and utility of 趣赢平台-led research products, and communicating with scientific communities concerning our competencies and scientific offerings. In addition to this work, she currently oversees a large electronic health record (EHR) network examining respiratory infection vaccine effectiveness and has planned and implemented several multisite epidemiologic studies to examine vaccine effectiveness.
Education
- ScD, Maternal and Child Health, Harvard School of Public Health
- MS, Maternal and Child Health, Harvard School of Public Health
- MPH, Epidemiology and Biostatistics/Social and Behavioral Health, Boston University School of Public Health
- BA, Psychology, Hamilton College
-
Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry
European Urology
January 2023
F. Chen, R.K. Madduri, A.A. Rodriguez, B.F. Darst, A. Chou, X. Sheng, A. Wang, et al.
DOILink for: Evidence of novel susceptibility variants for prostate cancer and a multiancestry polygenic risk score associated with aggressive disease in men of African ancestry -
Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021–2022 season, VISION Network
Journal of Infectious Diseases
January 2023
M.W. Tenforde, Z.A. Weber, M.B. DeSilva, E. Stenehjem, D.-H. Yang, B. Fireman, M. Gaglani, et al.
DOILink for: Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021–2022 season, VISION Network -
Emerging ENDS products and challenges in tobacco control toxicity research
Tobacco Control
January 2022
R.M. Strongin, E. Sharma, H.C. Erythropel, A. El-Hellani, N.O.F. Kassem, V.B. Mikheev, A. Noël, et al.
DOILink for: Emerging ENDS products and challenges in tobacco control toxicity research